Project Grant R61CA281785
Award Date 5/1/24
Completion Date 4/30/25
Dollars Obligated $1.5M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $457,683 to the Beckman Research Institute of the City of Hope to develop and evaluate novel "Bio-Beacons" - tumor-targeting bacterial vectors engineered to secrete chemokines and cytokines. The goal is to increase the density of tumor-reactive immune cells, such as CD8 T cells, CD4 T cells, dendritic cells, and natural killer cells, within solid tumors. This is...
- Federal Grant Award Summary Aerocytek, Inc. received a $400,000 Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) to develop point-of-care autologous CAR-T (Chimeric Antigen Receptor T-cell) cell manufacturing technologies. The project, initiated on September 18, 2025 and concluding August 31, 2026, addresses critical manufacturing capacity constraints that have resulted in patient treatment delays and mortality, particularly among...
- Federal Grant Award Summary Cellchorus Inc. received a $399,625 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) to develop functional biomarkers for predicting patient response to Chimeric Antigen Receptor (CAR) T-cell therapy. The project, which commenced September 1, 2025 and concludes August 31, 2026, leverages the company's proprietary Time-lapse Imaging Microscopy in Nanowell Grids (TIMING) platform—an artificial...
- Pumpkinseed Technologies Inc. received a $353,204 Phase I Small Business Innovation Research (SBIR) Project Grant award from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) on June 19, 2025, with completion targeted for April 30, 2026. The award funds development and proof-of-concept demonstration of Cell-MAPP (Cell Monitoring Against Presented Peptides), a novel technology that enables dynamic, real-time monitoring of individual T cell states during antigen...
- Rattan Life Science Inc. received a $275,000 Project Grant award from the National Science Foundation under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) to develop a platform for generating induced pluripotent stem cell-derived naïve CD4+ and CD8+ T cells with fidelity, reproducibility and scalability. The platform employs proprietary induced thymic epithelial cells to provide biologically relevant thymic positive selection signals during T cell differentiation,...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) is providing $827,942.00 to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University to investigate a novel inhibitory receptor that regulates the persistence and function of chimeric antigen receptor (CAR)-engineered T cell therapy for lymphoma. The key objectives are to: 1) examine the causal role of this inhibitory receptor axis in impairing the therapeutic...
- The National Cancer Institute (NCI), under the federal Cancer Biology Research grant program (CFDA 93.396), awarded a $218,089 Project Grant to the University of California, Santa Barbara (UCSB) to develop and evaluate a novel chimeric antigen receptor macrophage (CAR-M) immunotherapy for the treatment of triple-negative breast cancer (TNBC). The project, titled "RAC-Enhanced Chimeric Antigen Receptor-Macrophage (RACE-CAR-M) Immunotherapy for Triple Negative Breast Cancer," aims to...
- The New York University (NYU) School of Medicine was awarded a $1,525,500 Project Grant by the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310). The grant funding, which runs from September 1, 2024 to August 31, 2027, supports the development of new technologies to address two major bottlenecks in the chimeric antigen receptor (CAR) T cell therapy development process: identifying tumor-specific antigens and engineering...
- Blood Cell Technologies LLC received a $400,000 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), awarded on September 1, 2025, with completion targeted for August 31, 2026. The award funds development of second-generation BLVRB (biliverdin IXB reductase) inhibitors designed to treat chemotherapy-induced thrombocytopenia (CIT), a dose-limiting toxicity affecting approximately 50% of chemotherapy patients with hematologic malignancies...
- Federal Grant Award Summary Massachusetts General Hospital received a $2.91 million Project Grant from the National Institutes of Health Office of the Director under the Trans-NIH Research Support program (CFDA 93.310), awarded on August 6, 2025, with completion targeted for July 31, 2028. The grant funds research to develop chimeric antigen receptor (CAR) natural killer (NK) cell therapy as an effective immunotherapy against solid tumors, including lung, breast, prostate, and colorectal...